Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Planet82 was a South Korean nanotechnology company that gained international notoriety in the mid-2000s for its 'Single Carrier Modulation Photo Detector' (SMPD) technology, which it claimed could capture high-resolution images in near-total darkness. The company also developed 'AccuFat,' a near-infrared body fat meter intended for clinical and consumer healthcare applications, including obesity management and metabolic monitoring. However, the company became the center of one of South Korea's largest stock manipulation scandals when its technological claims were found to be fraudulent or significantly exaggerated. Planet82 was delisted from the KOSDAQ in 2008, and its leadership faced criminal prosecution for fraud and stock manipulation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Planet82.